Data edition of
Residue An evidence-graded reference for peptide science

Sermorelin dosage in clinical trials

What dose levels researchers actually tested, quoted from the trial registry and the published reports — so the numbers circulating online can be checked against their source.

Doses in published trials

Table 1. Dose arms of the principal published Sermorelin trials, as reported in the cited paper.
TrialPopulationDose armsScheduleRef.
Randomized vs growth hormone (1993)Children with GH deficiency of hypothalamic origin; n=60, 20 per arm30 µg/kg/day; 60 µg/kg/day (comparator: GH 0.1 IU/kg/day)Continuous SC infusion, 6 months1
Pediatric treatment (1999 review)Prepubertal children with idiopathic GH deficiency30 µg/kgOnce daily SC at bedtime; 12 months, limited data to 36 months2
Diagnostic test (1999 review)Children being tested for GH deficiency1 µg/kgSingle IV dose, with conventional tests2
Pharmacokinetics (1993)Healthy men aged 19–43; n=300.25–2 µg/kg IV (max GH response at 1–2 µg/kg); about 50 µg/kg intranasalSingle doses; intranasal also given three times in one day3

ClinicalTrials.gov lists 27 Sermorelin studies, but none of their registered arms names Sermorelin together with a dose, so this page quotes the published reports only.

References

Every source below was retrieved from its official API or page and cached on the data-edition date. Numbers match the margin notes.

  1. 1 PubMed Chen RG, Shen YN, Yei J, et al. A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency. Acta Paediatr Suppl 1993. PMID 8329830; doi:10.1111/j.1651-2227.1993.tb12834.x.
  2. 2 PubMed Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs 1999. PMID 18031173; doi:10.2165/00063030-199912020-00007.
  3. 3 PubMed Wilton P, Chardet Y, Danielson K, et al. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl 1993. PMID 8329825; doi:10.1111/j.1651-2227.1993.tb12827.x.

← Sermorelin monograph · Why we publish trial doses